Ibuprofen Gen.Orph

Ibuprofen, the active ingredient in Ibuprofen Gen.Orph, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an intravenous solution for intravenous use. It provides analgesic, antipyretic and anti‑inflammatory effects for patients experiencing pain, fever, postoperative discomfort or musculoskeletal inflammation in hospital settings. It is indicated for acute and chronic conditions where rapid onset of action is required.

GNH USA supplies Ibuprofen Gen.Orph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare institutions.

Ibuprofen administered intravenously acts on inflammatory pathways to relieve several acute conditions.

- Pain: Provides rapid analgesia for acute surgical and trauma‑related pain. - Fever: Reduces elevated body temperature in postoperative and infectious settings. - Inflammation: Diminishes swelling and inflammatory response after orthopedic procedures. - Postoperative pain: Controls discomfort during the immediate recovery period. - Musculoskeletal pain: Alleviates pain associated with sprains, strains and musculoskeletal injuries.

Adverse reactions may occur with intravenous ibuprofen and are categorized by frequency.

Common Side Effects: - Nausea: Mild to moderate upset stomach. - Vomiting: Occasional emesis following infusion. - Headache: Transient headache during or after administration. - Dizziness: Light‑headed sensation, especially with rapid infusion. - Injection site pain: Discomfort at the IV access point. - Elevated blood pressure: Small rise in systolic/diastolic values.

Serious or Rare Side Effects: - Gastrointestinal bleeding: Potential ulceration or hemorrhage. - Renal impairment: Acute kidney injury in susceptible patients. - Severe allergic reactions: Anaphylaxis, angioedema, or urticaria. - Stevens‑Johnson syndrome: Rare mucocutaneous eruption. - Hepatotoxicity: Elevated liver enzymes or liver injury. - Thrombocytopenia: Decreased platelet count leading to bleeding risk.

Prior to using intravenous ibuprofen, clinicians should evaluate patient‑specific risk factors.

- Renal function: Monitor serum creatinine and urine output in patients with existing kidney disease. - Bleeding risk: Avoid in individuals with active gastrointestinal ulceration or coagulopathy. - Cardiovascular status: Use cautiously in patients with uncontrolled hypertension or heart failure. - Pregnancy: Reserve for situations where benefits outweigh potential fetal risks. - Drug interactions: Review concomitant NSAIDs, anticoagulants, or corticosteroids for additive toxicity. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Ibuprofen can affect the safety or efficacy of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): Increased risk of serious bleeding. - Other NSAIDs: Additive gastrointestinal toxicity and ulcer risk. - Corticosteroids: Heightened potential for gastric ulceration.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: Combined use can impair renal function. - Lithium: Ibuprofen can raise lithium serum concentrations. - Methotrexate: Reduced clearance leading to toxicity.